drugset / Trial / NCT02728947

Pharmacokinetic Profile of Neupro Patch Administrated at 2 mg, 4 mg, 6 mg and 8 mg/Day Weekly in Patients With Early-stage Parkinson's Disease

NCT02728947

Phase 1 Completed 28 enrolled Luye Pharma Group Ltd.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To study the profile of Neupro patch administrated at 2 mg, 4 mg, 6 mg and 8 mg/day weekly in patients with early-stage Parkinson's disease

Timeline

Start
2016-05
Primary completion
2016-08
Completion
2016-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Rotigotine Unknown 2 mg Other
Comparator Rotigotine Unknown 4 mg Other
Comparator Rotigotine Unknown 6 mg Other
Comparator Rotigotine Unknown 8 mg Other

Indications